Algernon Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Breathtec Biomedicala medical diagnostics company focused on developing, in-licensing, and commercializing proprietary innovative. Breathtec Biomedical (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Their efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung and breast cancers, neurodegenerative diseases like Alzheimer's, Parkinson's, tuberculosis, diabetes, liver disease, and more.
Algernon Pharmaceuticals has raised $1.4M across 2 funding rounds on record, the most recent a Post-IPO Equity of $1.4M announced in Aug 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Algernon Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Algernon Pharmaceuticals Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Algernon Pharmaceuticals announced a Post-IPO Equity in Jun 2022; the amount was not disclosed.
2 months later, a Post-IPO Equity of $1.4M was announced in Aug 2022.
Algernon Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Algernon Pharmaceuticals Funding Compared to Other Biotechnology Startups
Algernon Pharmaceuticals' latest round of $1.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Algernon Pharmaceuticals in Biotechnology and Delta
Companies Similar to Algernon Pharmaceuticals
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Algernon Pharmaceuticals Funding FAQs
What does Algernon Pharmaceuticals do?
Breathtec Biomedicala medical diagnostics company focused on developing, in-licensing, and commercializing proprietary innovative. Breathtec Biomedical (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Their efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung and breast cancers, neurodegenerative diseases like Alzheimer's, Parkinson's, tuberculosis, diabetes, liver disease, and more.
How much funding has Algernon Pharmaceuticals raised?
Algernon Pharmaceuticals has raised $1.4M across 2 rounds on record. The most recent is a Post-IPO Equity of $1.4M announced in Aug 2022.
When did Algernon Pharmaceuticals last raise funding?
Algernon Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $1.4M, announced in Aug 2022.
Who is the CEO of Algernon Pharmaceuticals?
Christopher J Moreau is listed as CEO at Algernon Pharmaceuticals.
Where is Algernon Pharmaceuticals headquartered?
Algernon Pharmaceuticals is based in Delta, Ontario, Canada.
How many employees does Algernon Pharmaceuticals have?
Algernon Pharmaceuticals is in the 1-10 employee band.
How does Algernon Pharmaceuticals' funding compare to other Biotechnology startups?
Algernon Pharmaceuticals' latest round of $1.4M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Algernon Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Algernon Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.